CA
NZ
UK
AU
IND
US
● Legend Biotech's five-year CARTITUDE-2 Cohort A data showed 50% of 20 patients remained progression-free after one CARVYKTI infusion.
● Healthcare Triangle cut its maximum equity-line draw per notice from $2.5 million to $250,000 in a September 22, 2026 amendment.
● OrbiMed Advisors and two affiliated funds disclosed a new 11.0% stake of 6,885,170 shares in Electra Therapeutics on September 25, 2026.
● Cencora, Inc. (NYSE:COR) appointed former Ryder System CEO Robert Sanchez to its board effective October 1, 2026.
● Co-Diagnostics failed to reach quorum at its annual meeting on both September 3 and September 24, 2026.
● Alterity Therapeutics scheduled itsAnnual General Meetingfor 11:00 a.m. AEDT on Friday, November 20, 2026.
● Aquestive Therapeutics furnished an updated corporate investor presentation to the SEC as Exhibit 99.1 on September 23, 2026.
● Acadia's Phase 2 RADIANT study narrowly missed its primary endpoint on the SAPS-H+D scale at six weeks.
● A Tennessee federal court granted preliminary approval on September 1, 2026 to settle four consolidated derivative lawsuits.
Momentum stocks tend to follow a familiar pattern. Strong runs attract new buyers, pullbacks test conviction, and the stocks that hold their gains through those pullbacks often have the strongest fundamental support. Today's session offers a small data point on that test.
Please wait processing your request...